GE Medical Systems has launched a new package for prostate cancer diagnosis that combines MR spectroscopy with conventional MR imaging. GE hopes the package, called PROSE, will reduce the number of biopsies experienced by prostate cancer patients.
The MRI portion of PROSE shows physicians where potentially cancerous prostate tissue is located, while the MR spectroscopy arm measures the chemical composition of prostate tissue to determine if cancer is present, and if so evaluates its stage and aggressiveness.
PROSE could eliminate multiple tissue biopsies that are sometimes required beyond the original biopsy in patients with elevated prostate-specific antigen (PSA) levels. If a patient has an elevated PSA but negative biopsy, PROSE could be used to confirm that the patient is cancer-free, and to localize and stage the tumor if cancer exists. If a patient has an elevated PSA and a positive biopsy, PROSE can localize and stage the tumor less invasively than using additional biopsies, GE said.
By AuntMinnie.com staff writersMay 5, 2003
Related Reading
GE gets FDA nod for Excite 3-tesla unit, April 15, 2003
GE reports 12% growth in medical systems sales, April 14, 2003
VHA renews GE deal, April 7, 2003
GE echo business surges, April 4, 2003
GE, Instrumentarium deal may be in trouble, April 4, 2003
Copyright © 2003 AuntMinnie.com
